This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tierney, R.
Right arrow Articles by Bell, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tierney, R.
Right arrow Articles by Bell, A.

 Previous Article  |  Next Article 

Journal of Virology, September 2007, p. 10092-10100, Vol. 81, No. 18
0022-538X/07/$08.00+0     doi:10.1128/JVI.00358-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Epstein-Barr Virus Exploits BSAP/Pax5 To Achieve the B-Cell Specificity of Its Growth-Transforming Program{triangledown}

Rosemary Tierney,1 Jasdeep Nagra,1 Isabel Hutchings,1 Claire Shannon-Lowe,1 Markus Altmann,2 Wolfgang Hammerschmidt,2 Alan Rickinson,1* and Andrew Bell1

Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom B15 2TT,1 Department of Gene Vectors, GSF-National Research Center for Environment and Health, Marchioninistrasse 25, 81377 Munich, Germany2

Received 19 February 2007/ Accepted 5 July 2007

Epstein-Barr virus (EBV) can infect various cell types but limits its classical growth-transforming function to B lymphocytes, the cells in which it persists in vivo. Transformation initiates with the activation of Wp, a promoter present as tandemly repeated copies in the viral genome. Assays with short Wp reporter constructs have identified two promoter-activating regions, one of which (UAS2) appears to be lineage independent, while the other (UAS1) was B-cell specific and contained two putative binding sites for the B-cell-specific activator protein BSAP/Pax5. To address the physiologic relevance of these findings, we first used chromosome immunoprecipitation assays and found that BSAP is indeed bound to Wp sequences on the EBV genome in transformed cells. Thereafter, we constructed recombinant EBVs carrying two Wp copies, both wild type, with UAS1 or UAS2 deleted, or mutated in the BSAP binding sites. All the viruses delivered their genomes to the B-cell nucleus equally well. However, the BSAP binding mutant (and the virus with UAS1 deleted) showed no detectable activity in B cells, whether measured by early Wp transcription, expression of EBV latent proteins, or outgrowth of transformed cells. This was a B-cell-specific defect since, on entry into epithelial cells, an environment where Wp is not the latent promoter of choice, all the Wp mutant viruses initiated infection as efficiently as wild-type virus. We infer that EBV ensures the B-cell specificity of its growth-transforming function by exploiting BSAP/Pax5 as a lineage-specific activator of the transforming program.


* Corresponding author. Mailing address: Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom B15 2TT. Phone: 44 121 414 4492. Fax: 44 121 414 4486. E-mail: a.b.rickinson{at}bham.ac.uk

{triangledown} Published ahead of print on 11 July 2007.


Journal of Virology, September 2007, p. 10092-10100, Vol. 81, No. 18
0022-538X/07/$08.00+0     doi:10.1128/JVI.00358-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Kelly, G. L., Rickinson, A. B. (2007). Burkitt Lymphoma: Revisiting the Pathogenesis of a Virus-Associated Malignancy. ASH Education Book 2007: 277-284 [Abstract] [Full Text]